Calcitonin gene-related peptide monoclonal antibody

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.[1][2] CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.

Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.[2][3]

Drugs[edit | edit source]

Currently FDA-licensed CGRP mAbs are:

Uses[edit | edit source]

A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve pain in patients who also had migraines.[4]

News and articles[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. "Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies". The Migraine Trust. Retrieved October 12, 2021.
  2. 2.0 2.1 2.2 "What are the new drugs for the treatment of migraines?". Retrieved October 12, 2021.
  3. Negro, Andrea; Martelletti, Paolo (June 2019). "Gepants for the treatment of migraine". Expert Opinion on Investigational Drugs. 28 (6): 555–567. doi:10.1080/13543784.2019.1618830. ISSN 1744-7658. PMID 31081399.
  4. Kang, Seung Ah; Govindarajan, Raghav (2021). "Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache". Muscle & Nerve. 63 (4): 563–567. doi:10.1002/mus.27153. ISSN 1097-4598.